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Abstract 
Introduction: The aim of the study is to investigate the usefulness of ultrasound combined with computed tomography (CT) for distin-
guishing between primary thyroid lymphoma (PTL) and Hashimoto’s thyroiditis (HT).
Material and methods: The investigation was conducted retrospectively in 80 patients from January 2000 to July 2018. All patients underwent 
pathological tests to be classified into one of two groups: PTL group and HT group. The cut-off value of CT density was determined using 
receiver-operating characteristic (ROC) curve analysis. The accuracy, sensitivity, specificity, positive predictive value (PPV), and negative 
predictive value (NPV) of diagnosis for thyroid by CT alone, ultrasound alone, and the combination of CT plus ultrasound were calculated.
Results: Of the 80 study patients, 27 patients were PTL and 53 patients were HT. Mean CT density had a sensitivity of 90.6% and a specific-
ity of 88.9% at a cut-off value of 53.5 HU, with area under the curve (AUC) 0.88. Ultrasound combined with CT had the highest specificity, 
accuracy, and PPV compared with CT alone and ultrasound alone (p value < 0.05). 
Conclusions: Features such as extremely hypoechogenicity, enhanced posterior echo, cervical lymphadenopathy in ultrasound image, 
and linear high-density strand signs, and very low density in CT imaging have high sensitivity and specificity in thyroid lymphoma. 
Therefore, ultrasound combined with CT may be useful for distinguishing between PTL and HT.  (Endokrynol Pol 2019; 70 (6): 463–468)
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Introduction
Primary thyroid lymphoma (PTL) is a rare thyroid 
tumour, representing approximately 5% of all thy-
roid malignancies and accounting for less than 2% 
of extranodal malignant lymphomas [1–3]. Despite 
the rarity of PTL, it is important to recognise PTL 
promptly because of different management of all 
the other thyroid neoplasms [4]. PTL occurs mostly 
in patients aged 60–70 years, and the incidence in 
women is higher than in men [5, 6]. It is estimated 
that approximately 60–90% of most PTL cases occur 
in the background of thyroiditis. One of the many 
theories that has been proposed to explain the basis 
is that chronic antigenic stimulation of lymphocytes 
in autoimmune disorders may lead to malignant 
transformation [8]. A minority support the theory of 
aberrant somatic hypermutation [9].
Hashimoto’s thyroiditis (HT) is known to be 
characterised by serological test and ultrasound 
examination, increased antithyroglobulin and anti-
thyroperoxidase antibody, and typical micronodular 
or microcystic change (1–6 mm) with surrounding 
echogenic septations in ultrasonic images combined 
with other clinical information has been considered 
as suggestive of benign disease [10–12]. By contrast, 
a few cases of evaluation of PTL by ultrasound and 
computed tomography (CT) have been reported, with 
confused and atypical features in the images [13]. The 
differences in the findings on ultrasound and CT be-
tween PTL and HT were not distinctly addressed. In 
addition, decreased CT density of HT compared with 
normal thyroid gland has been reported in a small 
number of cases. However, the difference in CT density 
between PTL and HT is unclear. 
PTL is often curable without extensive surgery if 
it is diagnosed early and treated appropriately [14, 
15]. Therefore, a suspicion of PTL by the radiologist 
or clinician is important for the early diagnosis and 
prompt treatment of this potentially curable thyroid 
malignancy. Therefore, the aim of this study was to 
investigate the usefulness of ultrasound combined with 
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because of an undefined result. All the pathology diagnosis was 
according to the 2018 WHO new classification standard. The PTLs 
in this study were classified as marginal zone B-cell lymphoma 
(MALT) or diffuse large B-cell lymphoma (DLBCL) and follicle 
centre lymphoma (FCL).  
Statistical analysis
The cytology and pathology results served as the reference standard 
for malignancy. Statistical analyses were performed with SPSS 
software for Windows v19.0 (IBM, USA). Non-normal distributed 
data were presented as median (interquartile range). The age 
and sex distribution of the two groups were determined by the 
chi-square test and Student’s t-test (95% confidence interval). The 
cut-off values of CT density were determined using the ROC curve. 
The level of statistical significance was defined as p < 0.05 with 
a confidence interval of 95%.
Results
Of the 27 PTL patients, nine patients were diagnosed with 
MALT, 16 patients were diagnosed with DLBCL, and two 
patients were diagnosed with FCL. Twenty-seven cases of 
PTL (five males and 22 females), aged 68 years (mean age 
68 ± 14 years). The tumours involved the right (n = 7), 
left (n = 7), or both lobes (n = 5) of the thyroid gland. The 
specific lobe of the thyroid gland involved was unknown 
in eight cases: 53 cases of HT (12 males and 41 females), 
aged 63 years (mean age 63 ± 13 years). All the patients 
displayed elevated levels of thyroid antibodies, such as 
anti-TG or anti-TPO antibodies. The sex distribution of 
the two groups was not significantly different. The ages 
in the PTL group were significantly higher than those in 
patients with HT (p < 0.00). Nine patients (33%) in the 
PTL group and 23 patients (43%) in the HT group pre-
sented with a rapidly enlarging anterior neck mass. Other 
associated symptoms included dyspnoea, hoarseness, 
dysphagia, and cough in both groups. Six patients in the 
PTL group and 15 in the HT group had no clinical symp-
toms. There was no significant difference between two 
groups in terms of clinical symptoms. Table I summarises 
the demographic findings in 80 patients. 
CT density based on Hounsfield units for the min, 
max, and average for each lesion was derived from the 
non-contrast images. The ROC curve used to evaluate 
the mean CT value, max CT value, and min CT value for 
differentiation of PTL from HT is shown in Figure 1. As 
shown in the figure, the area under the ROC curve was 
0.89 for mean CT value, 0.78 for max CT value, and 0.68 
for min CT value. A statistically significant difference 
of AUC was observed among mean CT value, max CT 
value, and min CT value. In our study, the cut-off value 
of mean CT was 53.5. The sensitivity and specificity of 
cut-off value were 90.6% and 88.9%, respectively. The 
mean CT values in the PTL group were significantly 
lower than those in patients with HT. Imaging studies 
of PTL showed the presence of marked hypoecho-
genicity in 19 patients, posterior acoustic enhancement 
CT for distinguishing between PTL and HT, which can 
help treatment rapidly.
Material and methods 
Patient selection
The study was approved by the institutional review board of 
the institution that provided the images and the Hospital Ethics 
Committee, and the ethics committee waived the need for writ-
ten, informed consent from each patient. This investigation was 
conducted retrospectively among 173 patients using a pathologic 
thyroid database at our institute between January 2000 and July 
2018. Subjects were excluded if they had been treated by chemo-
therapy and radiotherapy or if they had a history of resection of the 
thyroid. Certainly, studies lacking outcome measures or comparable 
results were also excluded. In order to be eligible for inclusion in 
the study, the data had to meet the following inclusion criteria: 
PTL or HT that was confirmed by surgical pathology; no previous 
biopsy before image evaluating or neoadjuvant chemotherapy; 
detailed examination (ultrasound, CT, serological test, etc.); and 
clinical information. Finally, 80 patients fulfilled the above criteria 
and were enrolled in the study. Among them, 27 patients were PTL 
and 53 patients were HT. 
The ultrasound examinations were performed by radiologists us-
ing 5–12 MHz linear array transducers. All images were obtained 
from patients who were scanned in a supine position with neck 
hyperextension in transverse and longitudinal planes. The three 
sonographic features were as follows: marked hypoechogenicity 
was defined as decreased echogenicity compared with neck strap 
muscle; cervical lymphadenopathy was defined as lymph nodes 
presenting with measurements of 5 mm or greater in the short 
axis, and the absence of a hyperechoic hilum, chaotic vascularity, 
calcification, a heterogeneous echotexture, or a cystic change; and 
posterior acoustic enhancement was defined as posterior echo-
genicity higher than the degree of the lesion.
The CT scan parameters used were as follows: thickness, 4.0 mm; 
spaces between slices, 4.0 mm; 120.0 kV; 165.0 mAs; 330.0 mA; field 
of view, 50 cm; matrix size, 512 × 512; and field reconstruction. 
We measured mean/min/max Hounsfield units of the thyroid on 
non-contrast CT image as CT number or CT value. In each case, 
a circular region of interest (ROI) of more than 30 mm2 in diameter 
was placed on one lobe with homogeneous density, without any 
calcification and also with minimal partial volume artefact. We mea-
sured five sections of the thyroid in order to avoid artefacts or areas 
of inhomogeneity. All the patients underwent contrast-enhanced 
scanning, which was attained with a rapid infusion of 100 mL of 
65% iodinated contrast material administered intravenously. The 
cut-off value of CT density was obtained by receiver operating 
characteristic (ROC) curve. Linear high-density strand sign in CT 
image was defined as linear high density within the lesion. 
Two radiologists evaluated the images, with more than eight years 
of experience. All the radiologists assessed the nodules for three 
features (marked hypoechogenicity, cervical lymphadenopathy, 
and posterior acoustic enhancement) in sonograms and one feature 
(linear high-density strand sign) in CT images. They interpreted 
the sonograms and CT images independently without any clini-
cal information about the patient, and their consensus was used 
strictly as the “truth” for the nodule imaging features. These two 
radiologists met and checked their own selections for agreement 
after the primary selection. Disagreements were resolved by reach-
ing a consensus through a short discussion and a third investigator 
was involved if necessary. At least two sonographic features were 
considered ultrasound positive. CT density < cut-off value or linear 
high-density strand sign was considered CT positive. 
Formalin-fixed tissue was available for haematoxylin-eosin (HE) 
staining. All of the pathologic specimens were viewed by a patholo-
gist with more than five years’ experience in thyroid pathology. In 
this study, five cases were submitted to the ULCA for consultation 
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in 17 patients, cervical lymphadenopathy in 16 patients, 
linear high-density strand sign in 17 patients, and CT 
density < 53.5 HU in 24 patients. For HT imaging stud-
ies, 24 of our patients were marked hypoechogenicity 
(45%), 20 were posterior acoustic enhancement (38%), 
28 were cervical lymphadenopathy (53%), 18 were linear 
high-density strand sign (34%), and five were CT den-
sity < 53.5 (9%). The specific data are shown in Table II.
The sensitivity, specificity, accuracy, positive predic-
tive value (PPV), and negative predictive value (NPV) 
of single ultrasound were 70.4%, 64.2%, 66.3%, 50.0%, 
and 81.0%, respectively, and for CT they were were 
85.2%, 58.5%, 67.5%, 51.1%, and 88.6%, respectively. 
After ultrasound and CT data were combined, the 
sensitivity, specificity, accuracy, PPV, and NPV were 
63.0%, 96.2%, 85.0%, 89.5%, and 83.6%, respectively. For 
the combined data compared with either ultrasound 
alone or CT alone, the specificity, accuracy, and PPV 
were statistically significant (p = 0.000, 0.001; p = 0.006, 
0.009; and p = 0.004, 0.004, respectively). Table III lists 
the sensitivity, specificity, PPV, NPV, and diagnostic 
accuracy for ultrasound, CT, and combined ultrasound 
and CT in detail.
There was showing a case as follows. A 65-year-old 
woman visited an endocrinology department complain-
ing of sudden neck enlargement for less than three 
months. The lesion was not painful. The results of all 
laboratory studies, including complete blood count, 
liver function tests, and thyroid hormone, were unre-
markable, although anti-TG and anti-TPO antibodies 
extremely elevated. Her medical and family histories 
were remarkable. Ultrasonography revealed posterior 
acoustic enhancement and cervical lymphadenopathy 
(Fig. 2). Enhanced CT scans of the neck showed linear 
high-density sign and CT mean density 34 HU. A biopsy 
specimen was obtained from the lesion. The histological 
study revealed DLBCL. Hematoxylin and eosin (H&E) 
staining showed that the tumour was composed of 
large cells with multiple morphology, abundant cyto-
plasm, irregular nuclear contour, deep nuclear stain, 
Table I. Comparison of clinical characteristics between 
patients with primary thyroid lymphoma (PTL) and 
Hashimoto’s thyroiditis (HT)
Clinical findings PTL (n = 27) HT (n = 53) p-value
Gender 0.67
  Women 22 41
  Men 5 12
Age (years) 0.00*
  Range 37–91 54–87
  Median 68 63
  Interquartile range 14 13
Symptoms 0.56
  Dyspnoea 4 2
  Hoarseness 2 0
  Dysphagia 5 10
  Cough 1 3
  Neck enlargement 9 23
  No symptom 6 15
*p < 0.05, difference was statistically significant
 














Figure 1. Receiver-operating characteristic (ROC) curve that 
evaluated the mean computed tomography (CT) number, max 
CT number, min CT number for differentiating primary thyroid 
lymphoma (PTL) from Hashimoto’s thyroiditis (HT)
Table II. Comparison between features of primary thyroid lymphoma (PTL) and Hashimoto’s thyroiditis (HT)
Ultrasound feature CT feature
Marked  
hypoechoic
Cervical 
lymphadenopathy
Posterior acoustic 
enhancement
Linear echogenic 
strand signs
CT density  
< 53.5 HU
PTL (27) 19 (70.4%) 16 (59.3%) 17 (63.0%) 17 (63.0%) 24 (88.9%)
HT (53) 24 (45.3%) 28 (52.8%) 20 (37.7%) 18 (34.0%) 5 (9.4%)
CT — computed tomography; HU — Hounsfield units
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and nucleolus. Immunohistochemical studies showed 
uniform expression of CD20, CD79a, CD10, Bcl-6, 
MUM-1, and CD21 and absence of Bcl-2, c-Myc, CD5, 
CD23, and cyclin-D1. The nuclear proliferation index 
as assessed by Ki-67 staining was approximately 90%. 
The patient was treated with eight courses of a standard 
CHOP (cyclophosphamide, doxorubicin, vincristine, 
and prednisone) chemotherapy regimen. She showed 
an excellent response to chemotherapy presenting 
shrinkage of thyroid volume. 
Discussion
The five-year survival rate of thyroid lymphoma with 
stage IE disease is as high as 75–89%, while year-year 
survival rate with stage IIE disease falls to 25–40% 
[16]. Therefore, the prognosis for thyroid lymphoma 
depends on staging, and early diagnosis is of vital 
importance [17–21]. When patients have coexistent HT 
with a rapidly growing thyroid mass or with symp-
toms of obstruction, a likely diagnosis may be HT with 
or without malignant lymphoma [22]. Ultrasound is 
a widely accepted diagnostic method for examining 
thyroid [23–27], but several studies have reported that 
it is less useful in differentiating between PTL and 
HT [28]. Ultrasound suffers the limitations of being 
non-specific [29–31]. CT has been introduced to an aug-
ment technique of diagnosis of thyroid disease [32]. 
However, if CT demonstrates low-attenuation mass in 
thyroid with additional features, for example, linear 
high-density strand sign, plus ultrasound evidence of 
marked hypoechogenicity, enhanced posterior echo, or 
cervical lymphadenopathy, the diagnosis is probably 
thyroid lymphoma [33].
Histologically, the thyroid is composed of follicles 
[34]. The follicles are filled with colloid that contains 
thyroid hormones produced from thyroglobulin and 
iodide, and the volume of colloid was found to be 
Table III. Diagnostic performance of ultrasound, computed tomography (CT), and combined ultrasound and CT
Examination 
method
Pathology
Accuracy Sensitivity Specificity NPV PPV
Malignant Benign
Ultrasound
Malignant 19 19
66.3% 70.4% 64.2% 81.0% 50.0%
Benign 8 34
CT
Malignant 23 22
67.5% 85.2% 58.5% 88.6% 51.1%
Benign 4 31
Combined 
ultrasound and CT
Malignant 17 2
85.0% 63.0% 96.2% 83.6% 89.5%
Benign 10 51
CT — computed tomography; NPV — negative predictive value; PPV — positive predictive value
Figure 2. A 65-year-old woman with diffuse large B-cell lymphoma (DLBCL). Longitudinal sonogram of left lobe shows posterior acoustic 
enhancement (A) and cervical lymphadenopathy (B). Longitudinal enhanced computed tomography (CT) scan shows presence of linear 
high-density sign (C). The transverse CT scan shows mean density of tumour 34 HU (D). DLBCL lymphoma of thyroid highlighting 
the abnormal lymphocyte in hematoxylin and eosin (H&E) stain (E). Immunohistochemical stain shows positive CD10 (F) and CD 20 
(G). Nuclear proliferation index as assessed by Ki-67 staining was approximately 90% (F)
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three times larger than the volume of the epithelial 
cells, which suggests that the CT density is high in the 
normal thyroid as a result of the large amount of col-
loid present [35]. On the other hand, reduced density 
not only reflects the decrease of iodine concentration 
in the thyroid follicles but also represents a decrease in 
colloid content and an increase in follicular cells [36]. HT 
induces lymphocyte infiltration into the thyroid, which 
replace normal follicles and reduces the formation 
and reserve of thyroid hormones [37]. PTL with sever 
densely proliferated cells compared with HT, which 
reduces CT density significantly. Linear high-density 
strand sign presented a compressed rim of unaffected 
thyroid tissue displaced in the lesion. 
Some sonographic findings of PTL were correlated 
with pathological findings in certain [38]. Orita et al. 
indicated that lymphoepithelial lesions containing neo-
plastic cells were consistent with hypoechoic areas of 
PTL [39]. Marked hypoechogenicity is the most typical 
appearance of PTL. Due to the extremely low level of 
internal echoes, nodular PTLs have been described as 
“pseudocysts” in previous studies. Fibrotic tissue and 
normal thyroid tissue were consistent with echogenic 
structures within or around the lesions. Densely and 
uniformly proliferated lymphoma cells in the lesion 
were possibly related with an enhanced posterior 
echo [40]. HT is considered as a risk factor for thyroid 
lymphoma development. In our study, all patients had 
a history of HT. Lymphoma was a malignant tumour 
originating from the lymphatic haematopoietic system 
leading to the enlargement of cervical lymph nodes [41]. 
Our results should be interpreted with an under-
standing of our study limitations. It is not certain that 
ultrasound combined with CT can definitely distinguish 
the PTL from HT. Also, IgG4 chronic thyroiditis will 
have these three characteristics (marked hypoecho-
genicity, cervical lymphadenopathy, posterior acoustic 
enhancement).  These patients will present as a false 
positive in their evaluation, resulting in a reduced 
PPV. Our study suggested that ultrasound combined 
with CT could be a diagnostic approach to diagnosis of 
PTL and HT; however, as we expected, there are some 
potential biases and limitations in our research. One 
of the major limiting factors is the selection bias. Also, 
the simple aspect of our study indicates that further 
well-designed and prospective studies are needed to 
verify our results.
Conclusions
This study evaluated the clinical value of ultrasound 
and CT features in differentiating between PTL and HT. 
Neither CT- nor ultrasound-specific features seem to 
have great diagnostic potential to differentiate between 
PTL and HT. Thus, we support the recommendation 
that ultrasound combined with CT could be used in 
clinical diagnosis as a noninvasive diagnostic approach, 
which may lead to a great improvement in accurate 
and early diagnosis, and for PTL, early preoperative 
diagnosis is crucial to help make the treatment protocol 
and improve the patient’s prognosis.
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